Jabarpour Maryam, Rashtchizadeh Nadereh, Ghorbani Haghjo Amir, Argani Hassan, Nemati Mahboub, Dastmalchi Siavoush, Roshangar Leila, Ranjbarzadhag Masoumeh, Mesgari-Abbasi Mehran, Bargahi Nasrin, Sanajou Davoud
Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Iran J Basic Med Sci. 2020 Feb;23(2):206-213. doi: 10.22038/IJBMS.2019.38239.9080.
Hypercholesterolemia is a common metabolic disorder in developing and developed countries and is associated with the increased rates of chronic kidney disease (CKD). Statin therapy could reduce cholesterol synthesis as well as progression of CKD. Diversity between statins causes variety in pharmacokinetics and pharmacodynamics and also their pleiotropic effects. In the present investigation we aimed to evaluate the protective potentials of both atorvastatin (Ator) (as lipid-soluble statin) and rosuvastatin (Ros) (as water-soluble statin) against renal histopathological damages in the high cholesterol diet induced hypercholesterolemic rats (HCDIHR).
Serum lipid profile, oxidized low density lipoprotein (OX-LDL), malondialdehyde (MDA), urea and creatinine levels, as well as renal histopathology were evaluated.
While Ros acted better than Ator to reduce serum low density lipoprotein cholesterol (LDL-C) (0.01), atherogenic index (AI) (0.01), MDA (0.01), and OX-LDL (0.01); no significant differences were noted in their cholesterol (0.72), triglyceride (TG) (0.79), and very low density lipoprotein cholesterol lowering (VLDL-C) (0.79) and high density lipoprotein cholesterol elevating effects (HDL-C) (0.72). Ator was more effective to reduce renal histopathologic indices compared to Ros, including accumulation of lipid droplet, glomerular foam cells, mesangial cell proliferation, renal hemorrhage, and tubulointerstitial damages in the kidneys of diet induced hypercholesterolemic rats.
The findings underline that the lipophilic Ator may performs better than Ros in attenuating renal damages in HCDIHR.
高胆固醇血症在发展中国家和发达国家都是一种常见的代谢紊乱疾病，并且与慢性肾脏病（CKD）发病率的增加相关。他汀类药物治疗可降低胆固醇合成以及CKD的进展。他汀类药物之间的差异导致了其药代动力学和药效学的多样性以及它们的多效性。在本研究中，我们旨在评估阿托伐他汀（Ator）（作为脂溶性他汀类药物）和瑞舒伐他汀（Ros）（作为水溶性他汀类药物）对高胆固醇饮食诱导的高胆固醇血症大鼠（HCDIHR）肾脏组织病理学损伤的保护潜力。
评估血清脂质谱、氧化低密度脂蛋白（OX-LDL）、丙二醛（MDA）、尿素和肌酐水平以及肾脏组织病理学。
虽然Ros在降低血清低密度脂蛋白胆固醇（LDL-C）（P<0.01）、致动脉粥样硬化指数（AI）（P<0.01）、MDA（P<0.01）和OX-LDL（P<0.01）方面比Ator表现更好；但在它们降低胆固醇（P=0.72）、甘油三酯（TG）（P=0.79）和极低密度脂蛋白胆固醇（VLDL-C）（P=0.79）以及升高高密度脂蛋白胆固醇（HDL-C）（P=0.72）的效果方面未观察到显著差异。与Ros相比，Ator在降低饮食诱导的高胆固醇血症大鼠肾脏的组织病理学指标方面更有效，包括脂滴积累、肾小球泡沫细胞、系膜细胞增殖、肾出血和肾小管间质损伤。
研究结果强调，在减轻HCDIHR的肾脏损伤方面，亲脂性的Ator可能比Ros表现更好。
